<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a clonal disorder characterized by increased stem cell proliferation coupled with aberrant differentiation resulting in a high rate of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and eventual symptoms related to <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Cellular differentiation is an epigenetic process that requires specific and highly ordered DNA methylation and <z:chebi fb="0" ids="15358">histone</z:chebi> modification programs </plain></SENT>
<SENT sid="2" pm="."><plain>Aberrant differentiation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> can often be traced to <z:mp ids='MP_0008877'>abnormal DNA methylation</z:mp> (both gains and losses of DNA methylation genome wide and at specific loci) as well as mutations in genes that regulate epigenetic programs (TET2 and DNMT3a, both involved in DNA methylation control; EZH2 and ASXL1, both involved in <z:chebi fb="0" ids="15358">histone</z:chebi> methylation control) </plain></SENT>
<SENT sid="3" pm="."><plain>The epigenetic nature of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may explain in part the serendipitous observation that it is the disease most responsive to DNA methylation inhibitors; other epigenetic-acting drugs are being explored in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as well </plain></SENT>
<SENT sid="4" pm="."><plain>Progression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is characterized by further acquisition of epigenetic defects as well as mutations in growth-controlling genes that seem to tip the proliferation/<z:mpath ids='MPATH_3'>apoptosis</z:mpath> balance and result in the development of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is clinically and physiologically <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, a case can be made that subsets of the disease can be largely explained by disordered stem cell epigenetics </plain></SENT>
</text></document>